Intercept Pharmaceuticals: Q2 Earnings Insights

 

Shares of Intercept Pharmaceuticals ICPT moved higher by 3.6% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 82.81% year over year to ($0.33), which beat the estimate of ($1.21).

Revenue of $96,576,000 up by 25.02% year over year, which beat the estimate of $82,950,000.

Looking Ahead

The upcoming fiscal year's Ocaliva net sales expected to be between $325,000,000 and $340,000,000.

Details Of The Call

Date: Jul 29, 2021

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/rzy83jid

Recent Stock Performance

52-week high: $55.59

Company's 52-week low was at $13.88

Price action over last quarter: Up 1.92%

Company Description

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!